ClinicalTrials.gg
Active, not recruitingNCT04408625PROCLAIMUpdated Jul 16, 2026

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

A Phase 1/2 interventional study of LY3884963 and Methylprednisolone in Frontotemporal Dementia, sponsored by Prevail Therapeutics. Active, not recruiting at 12 sites in 6 countries. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Prevail Therapeutics (part of Eli Lilly and Company) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
30 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Planned enrollment
43rd of 66
35 · median 60
Started
2020
with 7 others
Phase 1/2
5 of 103
2 open now
Primary completion
2029-11
later than 33 of 44 live
Registered
61st of 103
by date

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 43rd largest by planned enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2020, is one of 5 in phase 1/2, reaches primary completion later than 33 of the 44 other live ones, and was the 61st registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 30 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884963 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will follow up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.

03

Conditions studied

  • Frontotemporal Dementia

Keywords

  • Fronto-Temporal Dementia
  • Frontotemporal Dementia
  • Progranulin Mutations
  • FTD-GRN
  • Gene Therapy
  • Dementia Gene Therapy
  • AAV9
04

Who can participate

Ages eligible
30 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 30 to 85 years (inclusive), at the time of .
  • Body weight range of ≥40 kg (88 lbs) to ≤110 kg (242 lb) and a of 18 to 34 kg/m2.
  • Has symptomatic frontotemporal dementia (FTD), including mild behavioral, cognitive, motor or language impairment per Investigator's assessment (behavioral-variant FTD, primary progressive aphasia-FTD, FTD with corticobasal syndrome, or a combination of syndromes are allowed for enrollment).
  • Score ≥0.5 and ≤15 on CDR plus NACC FTLD sum of boxes (Cohorts 1-4 only). Note: In Cohort 5 only patients with CDR plus NACC FTLD with sum of boxes ≥0.5 and ≤9 AND global score of 0.5 or 1 will be enrolled.
  • Stable use of background medications at least 8 weeks prior to LY3884963 dosing.
  • Carrier of a pathogenic progranulin gene (GRN) mutation.
  • Negative screening test for Mycobacterium tuberculosis (MTB) or documented negative MTB test within 1year prior to screening.
  • Age- and gender-appropriate cancer screenings are up-to-date and completed.
  • Patient and/or patient's legally authorized representative has the ability to understand the purpose and risks of the study, and provide written informed consent and authorization to use protected health information.
  • Women of nonchildbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before Screening) or , defined as spontaneous amenorrhea for at least 2 years, with follicle stimulating hormone level in the postmenopausal range at Screening based on the central laboratory's range.
  • Men and women of (i.e., ovulating, premenopausal, and not surgically sterile) must use a highly effective method of consistently and correctly for the duration of the study, including the long term follow up. Highly effective methods of contraception are those that, alone or in combination, result in a failure rate of less than 1% per year when used consistently and correctly (i.e., perfect use) and include the following for female patients of childbearing potential:

    • Combined (estrogen and progestogen containing) oral, intravaginal, or transdermal hormonal contraception associated with inhibition of ovulation.
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation.
    • Intrauterine device.
    • Intrauterine hormone-releasing system.
    • Bilateral tubal ligation or bilateral tubal occlusion (performed at least 3 months prior to Screening).
    • Vasectomized partner (performed at least 3 months prior to Screening).
    • Sexual abstinence (no sexual intercourse), if in line with the patient's usual and preferred lifestyle.
  • Acceptable forms of contraception for male patients include:

    • Sexual abstinence (no sexual intercourse), if in line with the patient's usual and preferred lifestyle.
    • History of vasectomy (performed at least 3 months prior to Screening, with documented absence of sperm in the ejaculate) in combination with condom.
    • Condom with spermicide used together with highly effective female contraceptive methods if the female partner(s) is of childbearing potential (see above for list of acceptable female contraceptive methods).

Note: Individuals who are in exclusively same sex relationships (as their preferred and usual lifestyle) are not required to use contraception.

  • Men must agree to use a condom during any sexual intercourse (including male patients who have had a vasectomy) and abstain from sperm donation for the duration of the study, including long-term follow-up.
  • Women must agree to abstain from egg donation for the duration of the study, including long-term follow-up.
  • Women of childbearing potential cannot be pregnant or lactating/breastfeeding and must have a negative result for the serum pregnancy test (β-human chorionic gonadotropin) at Screening.
  • Patient must agree to abstain from blood donation for the first year following gene transfer.
  • Patient has a reliable study partner/informant (e.g. family member, friend) willing and able to participate in the study as a source of information on the patient's health status and cognitive and functional abilities.
  • Patient is not dependent on a walker or wheelchair.
  • Patient is living in the community (i.e. not in nursing home); some levels of assisted living may be permitted at the discretion of the investigator.
  • Pneumococcal pneumonia and shingles vaccines are required within 10 years of Screening allowed to be performed during Screening but must be given at least 4 weeks prior to initiation of regimen.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a significant CNS (central nervous system) disease other than frontotemporal dementia (FTD) that may cause FTD symptoms or confound study objectives.
  • Brain or cervical spine magnetic resonance image (MRI)/MRA imaging showing abnormality considered to prevent intracisternal magna (ICM) injection.
  • or to , and/or sirolimus use.
  • Clinical evidence of peripheral symmetric sensory polyneuropathy (stable sensory mononeuropathies and radiculopathies are not exclusionary).
  • Concomitant disease or condition within 6 months of screening that could interfere with, or treatment of which might interfere with, the conduct of the study or that would, in the opinion of the investigator, pose an unacceptable safety risk to the patient or interfere with the patient's ability to comply with study procedures
  • Clinically significant laboratory test result abnormalities assessed at screening.
  • Participation within 3 months prior to screening in another therapeutic drug or device study with purported disease-modifying effects on FTD, unless it can be documented that the patient received placebo only.
  • Any type of prior gene or cell therapy.
  • in the 4 weeks prior to Screening. NOTE: Pneumococcal vaccine and/or shingles vaccine administration is allowed at least 4 weeks prior to initiation of regimen.
  • Use of blood thinners in the 2 weeks prior to screening, or anticipated use of blood thinners during the study. Antiplatelet therapies are acceptable if the patient is medically able to temporarily stop 48 hours to 7 days (depending on the antiplatelet medication used) prior to and at least 48 hours after ICM injection and LP. Note: the use of blood thinners as part of prophylaxis or treatment of an emergent VTE or another AE during the study does not exclude the patient, unless there is a baseline high risk of thromboembolic events, and use of blood thinners is highly anticipated in the opinion of the Investigator.
  • Contraindications or intolerance to imaging methods (MRA, MRI, and/or computed tomography [CT]), including claustrophobia and intolerance to contrast agents used for MRI, MRA, or CT (including, but not limited to, gadolinium contrast agents and iohexol).
  • Contraindications to general anesthesia or deep sedation.
  • Positive urine test for drugs of abuse (including opiates, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription at Screening and on Day 1.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Initial Cohort - Low dose

    Biological: LY3884963 · Drug: Methylprednisolone · Drug: Optional Sirolimus · Drug: Optional Prednisone

  • Experimental
    Initial Cohort - Medium dose

    Biological: LY3884963 · Drug: Methylprednisolone · Drug: Optional Sirolimus · Drug: Optional Prednisone

  • Experimental
    Bridging Cohort - Low dose

    Participants enrolled in the Bridging Cohort will be assigned to either low or medium dose in an alternating manner

    Biological: LY3884963 · Drug: Methylprednisolone · Drug: Optional Sirolimus · Drug: Optional Prednisone

  • Experimental
    Bridging Cohort - Medium dose

    Participants enrolled in the Bridging Cohort will be assigned to either low or medium dose in an alternating manner

    Biological: LY3884963 · Drug: Methylprednisolone · Drug: Optional Sirolimus · Drug: Optional Prednisone

  • Experimental
    Cohort 5-Medium Dose

    Will enroll up to 10 participants with early phase of disease

    Biological: LY3884963 · Drug: Methylprednisolone · Drug: Optional Sirolimus · Drug: Optional Prednisone

Interventions

  • BiologicalLY3884963

    Participants will receive a single dose of LY3884963, administered intra cisterna magna

  • IV pulses every 2 weeks in the first 3 months.

  • DrugOptional Sirolimus

    At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

  • DrugOptional Prednisone

    If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation

    Time frame: 5 Years

  2. Sum of adverse reactions (ARs) and suspected ARs

    Time frame: 5 years

  3. Sum of serious ARs and serious suspected ARs

    Time frame: 5 years

  4. Incidence of procedure or treatment-emergent AEs

    Measured by brain and spine MRI

    Time frame: 5 years

  5. Change in AAV9, PGRN, and NfL immunogenicity in blood

    PGRN: progranulin protein. Measured by level of antibodies and ELISPOT

    Time frame: Days 7, 14, and 21 and at Months 1, 1.5, 2, 3, 6, 9, 12, 18, and 24

  6. Change in AAV9, PGRN, and NfL immunogenicity in CSF

    Measured by levels of antibodies.

    Time frame: Months 2, 6, 12, 18, and 24

  7. Change in PGRN levels in blood

    Time frame: Days 7, 14, and 21 and at Months 1, 1.5, 2, 3, 6, 9, 12, 18, and 24

  8. Change in PGRN levels in CSF

    Time frame: Months 2, 6, 12, 18, and 24

Secondary outcomes

  1. Change in CDR plus NACC FTLD

    CDR: Clinical Dementia Rating staging instrument. NACC FTLD: National Alzheimer's Coordinating Center frontotemporal lobar degeneration domains

    Time frame: Months 3, 6, 9, and 12

  2. Change in NfL levels in blood

    NfL: neurofilament light chain

    Time frame: Days 7, 14, and 21 and at Months 1, 1.5, 2, 3, 6, 9, and 12

  3. Change in NfL levels in CSF

    Time frame: Months 2, 6, and 12

07

Study locations

12 sites
  • k2 Medical Research-Maitland
    Maitland, Florida 32751-5669, United States
  • PPD Phase 1 Clinic, 100 West Gore Street, Suite 202
    Orlando, Florida 32806, United States
  • Lahey Hospital & Medical Center, 41 Burlington Mall Road
    Burlington, Massachusetts 01805, United States
  • Hospital of the University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street
    Philadelphia, Pennsylvania 19104, United States
  • Royal Prince Alfred Hospital, Brain & Mind Research Institute, 94 Mallet Street
    Camperdown, New South Wales 2050, Australia
  • UZ Leuven, Neurologie Herestraat 49
    Leuven, 3000, Belgium
  • AP-HM Hôpital de La Timone
    Saint-Pierre, Marseille 13386, France
  • Centre Mémoire de Ressources
    Lille, 59000, France
  • Le Ber, Institut du Cerveau et de la Moelle Epinière
    Paris, 75013, France
  • Hospital Clinic de Barcelona, Villaroel 170 Servicio de Neurología
    Barcelona, 08036, Spain
  • Hospital Universitario de Donostia, Servicio De Neurologia, Consultas Externas Neurologia, San Sebastian, Guipúzcoa
    Donostia / San Sebastian, 20014, Spain
  • University College London,Queen Square, Dementia Research Building, London,
    London, WC1N 3BG, United Kingdom
08

References and documents

Publications

  • Sevigny J, Uspenskaya O, Heckman LD, Wong LC, Hatch DA, Tewari A, Vandenberghe R, Irwin DJ, Saracino D, Le Ber I, Ahmed R, Rohrer JD, Boxer AL, Boland S, Sheehan P, Brandes A, Burstein SR, Shykind BM, Kamalakaran S, Daniels CW, David Litwack E, Mahoney E, Velaga J, McNamara I, Sondergaard P, Sajjad SA, Kobayashi YM, Abeliovich A, Hefti F. Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results. Nat Med. 2024 May;30(5):1406-1415. doi: 10.1038/s41591-024-02973-0. Epub 2024 May 14. PubMed 38745011 ↗
  • De BP, Rosenberg JB, Selvan N, Wilson I, Yusufzai N, Greco A, Kaminsky SM, Heier LA, Ricart Arbona RJ, Miranda IC, Monette S, Nair A, Khanna R, Crystal RG, Sondhi D. Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease. Hum Gene Ther. 2023 Sep;34(17-18):905-916. doi: 10.1089/hum.2023.067. PubMed 37624739 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for Nov 2029, 108 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2020
First posted
May 29, 2020
StartActual
Nov 9, 2020
Primary completionEst.
Nov 30, 2029
CompletionEst.
Nov 30, 2029
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04408625
Responsible party
Sponsor
First posted
May 29, 2020
Start date
Nov 9, 2020
Primary completion
Nov 30, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Jul 16, 2026

Study contacts

Travis Lewis, MD, PhD
study director · Prevail Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion